Global manufacturing review and land monetisation drive major divestment move.

AstraZeneca India Plans ₹3,400-Crore Sale of 64-Acre Bengaluru Manufacturing Site.

AstraZeneca’s Indian arm plans to sell its 64-acre manufacturing facility in North Bengaluru for an estimated ₹3,400 crore as part of a global review of its manufacturing and supply network. The divestment aligns with the company’s broader land monetisation strategy to unlock value from non-core assets. The prime land parcel has attracted interest from leading developers and corporates, including Sattva Group, Aurobindo Pharma, and RMZ. Located in a key North Bengaluru corridor, the land is valued at over ₹53 crore per acre, according to industry estimates. Previous attempts to sell were delayed by high valuation expectations. AstraZeneca had earlier considered positioning the facility as a running asset with contract manufacturing possibilities, subject to regulatory approvals. The move reflects a wider trend of corporates monetising land assets, with developers such as Godrej Properties and Prestige Group actively expanding land banks across major Indian cities.